Safety and efficacy of delpacibart zotadirsen in Duchenne muscular dystrophy mutations amenable to exon 44 skipping in the USA (EXPLORE44): a randomised, placebo-controlled, double-blind, phase 1/2 trial
Publication date: November 2026 Source: The Lancet Neurology, Volume 25, Issue 11 Author(s): Aravindhan Veerapandiyan, Jamie Eskuri, Chamindra G Laverty, Craig M McDonald, Han Phan, Edward C Smith, Carolina Tesi Rocha, Brenda Wong, Marc Morris, Yvonne Tami, Tara Carmack, Philip Kovach, Josiah J Herzog, Steven G Hughes, Yiming Zhu, Elizabeth J Ackermann, Kevin M Flanigan, EXPLORE44 Study Investigators
Safety and efficacy of delpacibart zotadirsen in Duchenne muscular dystrophy mutations amenable to exon 44 skipping in the USA (EXPLORE44): a randomised, placebo-controlled, double-blind, phase 1/2 trial. // The Lancet Neurology. – URL: https://www.sciencedirect.com/science/article/pii/S1474442226003376?dgcid=rss_sd_all
Safety and efficacy of delpacibart zotadirsen in Duchenne muscular dystrophy mutations amenable to exon 44 skipping in the USA (EXPLORE44): a randomised, placebo-controlled, double-blind, phase 1/2 trial. The Lancet Neurology. https://www.sciencedirect.com/science/article/pii/S1474442226003376?dgcid=rss_sd_all
“Safety and efficacy of delpacibart zotadirsen in Duchenne muscular dystrophy mutations amenable to exon 44 skipping in the USA (EXPLORE44): a randomised, placebo-controlled, double-blind, phase 1/2 trial.” The Lancet Neurology.
@article{article68763,
title = {Safety and efficacy of delpacibart zotadirsen in Duchenne muscular dystrophy mutations amenable to exon 44 skipping in the USA (EXPLORE44): a randomised, placebo-controlled, double-blind, phase 1/2 trial},
journal = {The Lancet Neurology},
url = {https://www.sciencedirect.com/science/article/pii/S1474442226003376?dgcid=rss_sd_all}
}